R & D Progress
R & D Progress by Year
YEAR 2010
Pilot Study of Probiotic Dietary Supplementation for Promoting Healthy Kidney Function in Patients with Chronic Kidney Disease
Poster Presentation Title:"Probiotic Dietary Supplementation in Chronic Kidney Disease Patients (CKD III and IV)-Preliminary Observations and Combined Data Analysis of a 6-month Pilot Scale, Randomized, Double Blind and Crossover Study Design in Argentina, Canada, Nigeria and USA.
Poster Presentation Title:"Kibow’s Pathway Through a Drug Like Validation for a Probiotic Dietary Supplement Targeted for Helping Maintain a Healthy Kidney Function
Poster Presentation Title:"Case Study of a Patient with Juvenile Diabetes and Nephropathy using a Probiotics as a Dietary Supplement for a Continuous Three Year Period
YEAR 2009
Poster Presentation Title: "Dietary Supplementation with Probiotic Formulation (Kibow Biotics®) on CKD III and IV patients – a Short Term Pilot Scale Study in Canada" presented at ASN 2009 (Oct. 27 to Nov. 1) in San Diego, CA
An Editorial: "Can the bowel substitute for the kidney in advanced renal failure? - Current Medical Research and Opinion, Vol.25, No.8, 2009, 1913-1918
Brief Article: "Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada." Current Medical Research and Opinion, Vol.25, No.8, 2009, 1919-1930
Poster presentation title: Probiotics for Kidney health – Gut Based Uremic Toxin Removal – “Enteric Dialysis™” – Natarajan Ranganathan, Ph.D., and Eli A Friedman, MD at the 5th Asian Conference on Lactic Acid Bacteria Microbes in Disease Prevention, held July 1-3, 2009, Singapore.
Enteric Dialysis™ - Brief introduction and its potential for CKD applications - Dr. N. Ranganathan – presented as an invited speaker at symposium 7 – Renal patient, at the Parenteral & Enteric Nutrition Society of Malaysia (PENSA) held June 5 – 7, 2009, Kuala Lumpur, Malaysia.
Enteric Dialysis™ - Brief introduction and its potential for CKD applications - Dr. N. Ranganathan – invited speaker at the XXIX annual conference, Indian Society of Nephrology held Feb 6 – 8, 2009, Kanyakumari, India.
YEAR 2008
Development of Room Temperature Stable Probiotics for CKD Applications - Presented at ASN 2008
Pilot Scale Human Clinical Trials with a Scientifically Validated Probiotic Formulation - Kibow Biotics® - With CKD Stage III and IV Patients (Mid-term and partial data analysis from Canada) - Presented at IDDST 2008
Oral ingestion of probiotics and fecal analysis in CKD III and IV patients - Preliminary observations - Presented at CPRD 2008
YEAR 2007
Pilot Clinical Trial of Probiotic Bacteria (Kibow Biotics®) in Chronic Kidney Disease (CKD)
Progress in devising a bowel based probiotic therapy for uremia
YEAR 2006
Progress in devising a bowel based probiotic therapy for uremia
In Vitro and In Vivo Assessment of Intraintestinal Bacteriotherapy in Chronic Kidney Disease
Effect of feeding Kibow Biotics® to cats and dogs in kidney failure
Preliminary clinical evaluation of Kibow Biotics®, a probiotic agent, on feline azotemia
YEAR 2005
Are Clinical Trials Warranted for a Dietary Supplement with Probiotics?
Initial Safety Studies of a Probiotic for Renal Insufficiency
Probiotics reduces Azotemia in Gottingen Minipigs
Probiotic Amelioration of Azotemia in 5/6th Nephrectomized Sprague-Dawley Rats
Short term effect of temperature on Kibow Biotics®
Evaluation of Commercial Probiotic Products for Azotemia
YEAR 2004
An introduction to Probiotics and its potential in Clinical applications
Comparative microbial viability analysis in two delivery formats-Gel caps or mixed with food/diet
Gut-Based Uremia Therapy : In vitro R&D Investigations of an Oral Probiotic Microbial Formulation with the Aid of a Simulated Human Intestinal Microbial Ecosystem (SHIME) Biochemical Reactor
Gut-Based Uremia Therapy : Oral Bacteriotherapy Effectively Reduces Severity of Azotemia in 5/6th Nephrectomized Mini Pigs
Gut based Uremia therapy: Continued in vitro and in vivo R&D investigations on the application of oral probiotic bacteriotherapy towards Chronic Kidney Disease (CKD) patients
Significance of dosage for effective clinical application of probiotics
Mode of Delivery and Dosage are important factors for Uremia Therapy with Probiotics
Probiotic Formulation in vitro effect on Phenol and p-Cresol levels
Initial Trial of Probiotic Bacteria as Therapy for Uremia in Dogs
Kibow Biotics is preferred and superior to yogurt for uremia applications
Model of Chronic Renal Failure in Miniature Pigs
Oral Probiotic treatment for Uremia in a Porcine Model of Chronic Renal Failure
Substitution of the kidney function by the bowel in Azotemia
YEAR 2003
Artificial Swallowable Kidney Formulation
Oral Bacteriotherapy Effectively Reduces Severity of Azotemia in 5/6th Nephrectomized Rats
Streptococcus thermophilus KB19 is a Potential component of a Probiotic Regimen Applicable in Enteric Dialysis for Uremia
Rate of Urea Hydrolysis by Streptococcus thermophilus KB19 is comparable to Soil Bacterium Bacillus pasteurii and Genetically Engineered Urealytic E.coli
Probiotics Extend Survival in Untreated 5/6 Nephrectomized Rats: Possible Use for Probiotics as An Adjunct in Chronic Renal Failure (CRF)®
YEAR 2002
Probiotics to Eliminate Nitrogenous Metabolites
A Novel Synbiotic for Augmenting Kidney Function
Urea Hydrolysis and Ammonia Uptake by Bacillus pasteurii
Urease Activity in Commercial Yogurt
Bacillus pasteurii: A Small Microbe with Huge Potential
A Nutraceutical Approach to Pre-Dialysis
Viability of Probiotics in Gastric Juice and Artificial Intestinal Fluid